Aprea Therapeutics Announces Proposed Public Offering of Common Stock
DOYLESTOWN, Pa., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR …
 
       
       
  
 
     
     
     
     
     
     
     
     
     
     
     
    